{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:11Z","timestamp":1792790531646,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00198-023-06877-6","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T15:58:48Z","timestamp":1692374328000},"page":"2047-2058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"34","author":[{"given":"X.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-Z.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-P.","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-543X","authenticated-orcid":false,"given":"M.-H.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"6877_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"issue":"4","key":"6877_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"317","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 317(4):722\u2013733","journal-title":"JAMA"},{"key":"6877_CR3","unstructured":"Tymlos [package insert] (2018) Waltham, MA: Radius Health, Inc; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/Label\/2018\/208743s003lbl.pdfAccessed June 10, 2019"},{"issue":"4","key":"6877_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00223-015-0050-1","volume":"98","author":"P Esbrit","year":"2016","unstructured":"Esbrit P, Herrera S, Portal-N\u00fa\u00f1ez S, Nogu\u00e9s X, D\u00edez-P\u00e9rez A (2016) Parathyroid hormone-related protein analogs as osteoporosis therapies. Calcif Tissue Int 98(4):359\u2013369","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"6877_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, ACTIVE Study Investigators et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"issue":"5","key":"6877_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G (2016) Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int 99(5):489\u2013499","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"6877_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100(2):697\u2013706","journal-title":"J Clin Endocrinol Metab"},{"key":"6877_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","volume":"97","author":"CA Moreira","year":"2017","unstructured":"Moreira CA, Fitzpatrick LA, Wang Y, Recker RR (2017) Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone 97:314\u2013319","journal-title":"Bone"},{"issue":"7","key":"6877_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30(7):1465\u20131473","journal-title":"Osteoporos Int"},{"key":"6877_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","volume":"86","author":"J Jolette","year":"2017","unstructured":"Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G (2017) Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol 86:356\u2013365","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"6877_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.7326\/M22-0684","volume":"176","author":"C Ayers","year":"2023","unstructured":"Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C (2023) Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians. Ann Intern Med 176(2):182\u2013195","journal-title":"Ann Intern Med"},{"issue":"13","key":"6877_CR12","doi-asserted-by":"publisher","first-page":"817662","DOI":"10.3389\/fphar.2022.817662","volume":"1","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Fang Y, Wu J, Huang G, Bin J, Liao Y, Shi M, Liao W, Huang N (2022) Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis. Front Pharmacol 1(13):817662. https:\/\/doi.org\/10.3389\/fphar.2022.817662","journal-title":"Front Pharmacol"},{"issue":"6","key":"6877_CR13","first-page":"340","volume":"43","author":"CL Ventola","year":"2018","unstructured":"Ventola CL (2018) Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T 43(6):340\u2013351","journal-title":"P T"},{"issue":"5","key":"6877_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bib\/bbx010","volume":"19","author":"S Vilar","year":"2017","unstructured":"Vilar S, Friedman C, Hripcsak G et al (2017) Detection of drug\u2013drug interactions through data mining studies using clinical sources, scientific literature, and social media. Brief Bioinform 19(5):863\u2013877. https:\/\/doi.org\/10.1093\/bib\/bbx010","journal-title":"Brief Bioinform"},{"key":"6877_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","volume":"36","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Trifiro G, Patadia V, Sturkenboom M (2013) Postmarketing safety surveillance: Where does signal detection using electronic health care records fit into the big picture? Drug Saf 36:183\u2013197","journal-title":"Drug Saf"},{"key":"6877_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH (2000) A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 23:533\u2013542","journal-title":"Drug Saf"},{"issue":"2","key":"6877_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.26599\/TST.2018.9010074","volume":"24","author":"ADR Parallel","year":"2019","unstructured":"Parallel ADR (2019) Detection Based on Spark and BCPNN. Tsinghua Science and Tech 24(2):195\u2013206. https:\/\/doi.org\/10.26599\/TST.2018.9010074","journal-title":"Tsinghua Science and Tech"},{"key":"6877_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/pds.5265","volume":"30","author":"M Hauben","year":"2021","unstructured":"Hauben M, Zou C, Bright S, Hung E (2021) More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis. Pharmacoepidemiol Drug Saf 30:1140\u20131141","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6877_CR19","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, Li X, Li C, Zhao B et al (2020) Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol 84:106601","journal-title":"Int Immunopharmacol"},{"key":"6877_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10:796\u2013803","journal-title":"Int J Med Sci"},{"key":"6877_CR21","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J, Li F (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Scientific rep 12:20601","journal-title":"Scientific rep"},{"issue":"7","key":"6877_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14656566.2019.1583208","volume":"20","author":"D Merlotti","year":"2019","unstructured":"Merlotti D, Falchetti A, Chiodini I, Gennari L (2019) Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opin Pharmacother 20(7):805\u2013811. https:\/\/doi.org\/10.1080\/14656566.2019.1583208","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"6877_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa450","volume":"105","author":"F Cosman","year":"2020","unstructured":"Cosman F, Peterson LR, Towler DA, Mitlak B, Wang Y, Cummings SR (2020) Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial. J Clin Endocrinol Metab 105(11):1\u201312","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"6877_CR24","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/03007995.2020.1824897","volume":"36","author":"PD Miller","year":"2020","unstructured":"Miller PD, Bilezikian JP, Fitzpatrick LA, Mitlak B, McCloskey EV, Cosman F, Bone HG (2020) Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin 36(11):1861\u20131872. https:\/\/doi.org\/10.1080\/03007995.2020.1824897","journal-title":"Curr Med Res Opin"},{"key":"6877_CR25","unstructured":"FDA FAERS public dashboard. Available at https:\/\/fifis.fda.gov\/extensions\/fpdwidgets\/2e01da82-13fe-40e0-8c38-4da505737e36.html. Accessed April 12, 2021."},{"key":"6877_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","volume":"43","author":"Y Song","year":"2020","unstructured":"Song Y, Xu Y, Lin Y, Zhao B, Qiang S (2020) Fractures due to aromatase inhibitor therapy for breast cancer: a real-world analysis of FAERS data in the past 15 Years. Oncol Res Treat 43:96\u2013102","journal-title":"Oncol Res Treat"},{"key":"6877_CR27","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang Y (2020) A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf 19:1505\u20131511","journal-title":"Expert Opin Drug Saf"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06877-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06877-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T09:02:34Z","timestamp":1700038954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06877-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6877"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06877-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}